Topline results from phase 2b clinical trial of UBX1325 for DME expected in Q1 2025

News
Article

This phase 2b study (ASPIRE) is currently underway.

Image credit: AdobeStock/J Bettencourt/peopleimages.com

(Image credit: AdobeStock/J Bettencourt/peopleimages.com)

UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual outcomes in DME patients by addressing treatment burdens and suboptimal responses seen with standard therapies.1

A phase 2b trial, dubbed ASPIRE, evaluating the safety and efficacy of UBX1325 compared to aflibercept is underway. Topline results from the 24-week primary endpoint data are expected in the first quarter of 2025, with 36-week data following in the second quarter of 2025. The study's endpoint for regulatory approval will assess best-corrected visual acuity (BCVA) using the ETDRS scale, a tool for assessing visual acuity measurements.Data from the ASPIRE study is expected to provide essential insights to inform the design of potential pivotal trials. 1

UNITY had a Type C interaction with the U.S. Food and Drug Administration (FDA) regarding the development of UBX1325. Based on this feedback, the company anticipates that a pivotal study would need to be a non-inferiority trial comparing UBX1325 to aflibercept.1

Reference:
1. UNITY Biotechnology Prepares For Key Data Readouts In 2025 For UBX1325 In Diabetic Macular Edema. UNITY Biotechnology, Inc. January 6, 2025. Accessed January 10, 2025. https://www.rttnews.com/3500679/unity-biotechnology-prepares-for-key-data-readouts-in-2025-for-ubx1325-in-diabetic-macular-edema.aspx?refresh=1

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Recent Videos
At EURETINA 2025, Stela Vujosevic, MD, PhD, FEBO asks, "as part of the symposium on diabetes and vascular disease, "Do we need a new staging for diabetic retinopathy and macular edema?"
1 expert in this video
© 2025 MJH Life Sciences

All rights reserved.